Vaccination with minor histocompatibility antigen-loaded donor DC vaccines to boost graft-versus-tumor immunity after allogeneic stem cell transplantation - MiHA-loaded DC vaccination after allogeneic SCT

Radboud University Nijmegen Medical Centre0 个研究点开始时间: 2012年8月24日最近更新: 2016年8月8日

适应症

试验速览

暂无简介。

•Patients with AML, myelodysplasia (MDS), ALL, CML (accelerated or blast phase), CLL, MM or malignant NHL, who underwent HLA-matched allo-SCT
•Patients positive for HLA-A2, HLA-A24, HLA-B7 and/or HLA-B44
•Patients positive for HA-1, LRH-1 and/or ARHGDIB transplanted with corresponding MiHA-negative donor
•Patients >18 and <65 years of age
•WHO performance 0-2
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 10
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Life expectancy < 3 months
•Severe neurological or psychiatric disease
•Progressive disease needing cytoreductive therapy
•HIV positivity
•Patients with acute GVHD grade 3 or 4
•Patients with extensive chronic GVHD
•Patients with active infections (viral, bacterial or fungal) that requires specific therapy. Acute anti-infectious therapy must have been completed within 14 days prior to study treatment
•Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease
•Severe pulmonary dysfunction (CTCAE III-IV)
•Severe renal dysfunction (serum creatinine > 3 times normal level)
•Severe hepatic dysfunction (serum bilirubin or transaminases > 3 times normal level)
•Patients with known allergy to shell fish

发起方

Radboud University Nijmegen Medical Centre